rs699947
rs699947 · 6 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | rs699947 | “Evaluating the Impact of rs4025935, rs71748309, rs699947, and rs4646994 Genetic Determinants on Polycystic Ovary Syndrome Predisposition-A Case-Control Study.” | 0.90 | hgvs_regex_v1 |
| variant | rs699947 | “DNA was extracted from the buffy coat and analyzed for VEGF polymorphisms (rs10434, rs3025053, rs699947, rs2010963, rs833061, and rs25648) using TaqMan Real-Time PCR.” | 0.90 | hgvs_regex_v1 |
| variant | rs699947 | “Hence it depicts that allele A of VEGF (rs699947) can increase the risk of RA while allele C has a protective role.” | 0.90 | hgvs_regex_v1 |
| variant | rs699947 | “VEGF levels in rs699947 (AA-major homozygous), rs3025039 (CC-major homozygous) and rs833061 (TT & CC-major & minor homozygous) genotypes were significantly higher in PCOS.” | 0.90 | hgvs_regex_v1 |
| variant | rs699947 | “The VEGF rs699947 SNP is located in the promoter region and is associated with susceptibility to breast carcinoma development.” | 0.90 | hgvs_regex_v1 |
| variant | rs699947 | “Increased T2DM risk was associated with rs699947, rs1570360, and rs3025020, while reduced T2DM risk was seen with rs1547651, rs2010963, rs25648, rs3025036, and rs3025039 genotypes, thus assigning T2DM susceptibility and protection, respectively.” | 0.90 | hgvs_regex_v1 |